

HYPONATREMIA IS A MARKER OF SEVERITY OF HIV DISEASE IN **COMBINED ANTIRETROVIRAL THERAPY-NAIVE PATIENTS:** A SINGLE CENTRE RETROSPECTIVE COHORT STUDY

BRACONNIER Philippe^{a, b}, DELFORGE Marc^a, GARJAU Maria^c, WISSING Karl Martin^{b, c}, DE WIT Stéphane^a

^aDepartment of Infectious Diseases, AIDS Reference Center, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium. ^bDepartment of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium. ^cDepartment of Nephrology, Centre Hospitalier Universitaire Brugmann, Brussels, Belgium.

OBJECTIVES	METHODS
 Hyponatremia is the most common electrolyte abnormality	 Single-center retrospective cohort study AIDS Reference Center, St Pierre University Hospital in
in the general patient population: ➢ Prevalence: 4-7% in an ambulatory setting and 15-30% in	Brussels, Belgium

- hospital care
- Hyponatremia is associated with an increased risk of death in hospitalized and in ambulatory patients

Study objectives:

- Investigate the prevalence of hyponatremia in HIV-infected patients in the recent cART-era
- Provide a detailed description of health conditions associated with hyponatremia
- Study hypothesis: hyponatremia is an independent risk factor for death of HIV-positive patients



- Collection of demographic, clinical and laboratory data
- Long term follow-up (15 years)
- The outcomes of interest were the occurrence of death and number of hospitalizations

RESULTS

Main characteristics	of hyponatremic	and normon	atremic pati	ients	Kaplan-Meier estimates of survival by natremia group	Scatter plot of natremia and CD4 count
Characteristics	Total (N=1196)	Na < 135 mmol/l	$Na \ge 135 \text{ mmol/l}$	P-value		Scatter Plot
		(N=177)	(N=1019)		Product-Limit Survival Estimates	150 - Observations 1185 Correlation 0.2992

Age (years) ¹	36.8 ± 10.7	$37.4{\pm}10.0$	36.7±10.9	0.238
Female gender (n)	445 (37.2%)	90 (50.8%)	355 (34.8%)	<0.0001
African ethnicity (n)	612 (51.2%)	125 (70.6%)	487 (47.8%)	<0.0001
Homo-bisexual orientation (n)	395 (33.0%)	26 (14.7%)	369 (36.2%)	<0.0001
Natremia (mmol/l) ²	139.0 (136.0-141.0)	132.0 (130.0-134.0)	139.0 (137.0-141.0)	<0.0001
Hospitalization at first contact (n)	332 (27.7%)	128 (72.3%)	204 (20.0%)	<0.0001
Acquired immunodeficiency syndrome (AIDS) (n)	215 (18.0%)	89 (50.3%)	126 (12.4%)	<0.0001
CD4 cell count $(/\mu l)^1$	371.8±275.3	207.5±197.7	400.4±277.0	<0.0001
CD4 cell count $< 350/\mu l$ (n)	611 (51.1%)	143 (80.8%)	468 (45.9%)	<0.0001
CD4 nadir $(/\mu l)^1$	362.8±267.6	200.8±184.1	391.2±269.9	<0.0001
CD4 nadir < $200/\mu l$ (n)	360 (30.1%)	106 (59.9%)	254 (24.9%)	<0.0001
HIV viral load (copies/ml) ²	71600 (13500-	100000 (55000-	58750 (11800-	<0.0001
	100000)	313500)	100000)	
HIV viral load > 100 000 copies/ml (n)	465 (38.9%)	104 (58.7%)	361 (35.4%)	<0.0001
Hepatitis B (n)	69 (5.8%)	14 (7.9%)	55 (5.4%)	0.223
Hepatitis C (n)	69 (5.8%)	12 (6.8%)	57 (5.6%)	0.478
Hepatitis C (n) Fib 4 score > 3.25 (n)	69 (5.8%) 77 (6.4%)	12 (6.8%) 28 (15.8%)	57 (5.6%) 49 (4.8%)	0.478 <0.0001
Hepatitis C (n) Fib 4 score > 3.25 (n) Anemia (n)	69 (5.8%) 77 (6.4%) 597 (50%)	12 (6.8%) 28 (15.8%) 138 (78%)	57 (5.6%) 49 (4.8%) 459 (45%)	0.478 <0.0001 <0.0001
Hepatitis C (n) Fib 4 score > 3.25 (n) Anemia (n) Hyperlipidemia (n)	69 (5.8%) 77 (6.4%) 597 (50%) 418 (34.9%)	12 (6.8%) 28 (15.8%) 138 (78%) 58 (32.8%)	57 (5.6%) 49 (4.8%) 459 (45%) 360 (35.3%)	0.478 <0.0001 <0.0001 0.550
Hepatitis C (n) Fib 4 score > 3.25 (n) Anemia (n) Hyperlipidemia (n) Mean triglyceridemia ¹	69 (5.8%) 77 (6.4%) 597 (50%) 418 (34.9%) 111.1±68.5	12 (6.8%) 28 (15.8%) 138 (78%) 58 (32.8%) 132.4±79.9	57 (5.6%) 49 (4.8%) 459 (45%) 360 (35.3%) 108.0±66.0	0.478 <0.0001 <0.0001 0.550 <0.0001
Hepatitis C (n) Fib 4 score > 3.25 (n) Anemia (n) Hyperlipidemia (n) Mean triglyceridemia ¹ Diabetes mellitus (n)	69 (5.8%) 77 (6.4%) 597 (50%) 418 (34.9%) 111.1±68.5 52 (4.3%)	12 (6.8%) 28 (15.8%) 138 (78%) 58 (32.8%) 132.4±79.9 14 (7.9%)	57 (5.6%) 49 (4.8%) 459 (45%) 360 (35.3%) 108.0±66.0 38 (3.7%)	0.478 <0.0001 <0.0001 0.550 <0.0001 0.0254
Hepatitis C (n) Fib 4 score > 3.25 (n) Anemia (n) Hyperlipidemia (n) Mean triglyceridemia ¹ Diabetes mellitus (n) Antihypertensive drugs (n)	69 (5.8%) 77 (6.4%) 597 (50%) 418 (34.9%) 111.1±68.5 52 (4.3%) 39 (3.3%)	12 (6.8%) 28 (15.8%) 138 (78%) 58 (32.8%) 132.4 \pm 79.9 14 (7.9%) 4 (2.2%)	57 (5.6%) 49 (4.8%) 459 (45%) 360 (35.3%) 108.0±66.0 38 (3.7%) 35 (3.4%)	0.478 <0.0001 <0.0001 0.550 <0.0001 0.0254 0.645
Hepatitis C (n) Fib 4 score > 3.25 (n) Anemia (n) Hyperlipidemia (n) Mean triglyceridemia ¹ Diabetes mellitus (n) Antihypertensive drugs (n) ¹ mean±standard deviation	69 (5.8%) 77 (6.4%) 597 (50%) 418 (34.9%) 111.1±68.5 52 (4.3%) 39 (3.3%)	12 (6.8%) 28 (15.8%) 138 (78%) 58 (32.8%) 132.4 \pm 79.9 14 (7.9%) 4 (2.2%)	57 (5.6%) 49 (4.8%) 459 (45%) 360 (35.3%) 108.0±66.0 38 (3.7%) 35 (3.4%)	0.478 <0.0001 <0.0001 0.550 <0.0001 0.0254 0.645





			•	
Characteristics	Total	Na < 135 mmol/l	Na≥135mmol/l	P-value
	(N=1196)	(N=177)	(N=1019)	
Follow-up (months) ¹	36.0 (9.0-80.0)	41.0 (4.0-115.0)	35.0 (10.0-77.0)	0.554
Loss to follow-up (n)	414 (34.6%)	71 (40.1%)	343 (33.7%)	0.104
Deaths (n)	63 (5.3%)	24 (13.5%)	39 (3.8%)	< 0.0001
Death rate/1000 patient-years (95% CI)	12.5 (9.6-16.0)	28.3 (18.1-42.2)	9.33 (6.6-12.7)	< 0.0001
Hospitalization rate/1000 patient-years (95% CI)	440 (422-458)	785 (725-845)	370 (252-388)	< 0.0001
Mean number of hospitalizations per patient $(n)^2$	2.2±4.9	4.3±9.5	1.8±3.3	< 0.0001
Median time to death (months) ¹	12.0 (3.0-34.0)	6.0 (2.0-22.5)	14.0 (4.0-39.0)	0.169
Median time to first hospitalization (months) ^{1,3}	12.0 (2.0-28.0)	2.0 (0.0-12.0)	13.0 (2.0-29.0)	0.0012

Outcomes in hyponatremic and normonatremic patients

³excluding patients hospitalized at first contact

Risk factors for mortality of patients in univariate/multivariate Cox's proportional hazard models

	Univariate Mod	lel	Multivariate Model		
Risk factors	Hazard ratio (95%	P-value	Hazard ratio (95%	P-value	
	Confidence interval)		Confidence interval)		
Age < 35 years	0.51 (0.29-0.87)	0.014	0.91 (0.48-1.73)	0.782	
Female gender	1.68 (1.01-2.80)	0.045	1.65 (0.86-3.16)	0.132	
African ethnicity	1.29 (0.77-2.15)	0.366			
Homo-bisexuel orientation	0.28 (0.13-0.59)	0.0003	0.90 (0.34-2.34)	0.827	
Na < 135mmol/l	3.94 (2.30-6.74)	< 0.0001	1.03 (0.54-1.97)	0.935	
AIDS	8.83 (5.18-15.06)	< 0.0001	5.24 (2.59-10.62)	< 0.0001	
CD4 cell count $< 350/\mu l$	11.71 (4.66-29.43)	< 0.0001	6.58 (1.89-23.06)	0.003	
HIV viral load > 100 000	3.36 (1.87-6.03)	< 0.0001	1.15 (0.56-2.37)	0.702	
copies/ml					
Hepatitis B	0.23 (0.032-1.71)	0.172			
Hepatitis C	2.54 (1.15-5.60)	0.0259	2.70 (1.172-6.23)	0.02	
Fib4 score > 3.25	3.84 (1.95-7.55)	< 0.0001	1.69 (0.77-3.74)	0.192	
Anemia	4.30 (2.95-6.27)	< 0.0001	1.15 (0.75-2.84)	0.263	
Hyperlipidemia	0.93 (0.54-1.59)	0.892			
Diabetes mellitus	4.22 (1.96-9.11)	0.0011	2.07 (0.88-4.85)	0.096	
Inclusion period 1998-2004	2.54 (1.52-4.25)	0.0004	1.32 (0.72 – 2.42)	0.372	

¹median (interquartile range)

²mean±standard deviation

³excluding patients hospitalized at first contact

CONCLUSIONS

- Baseline hyponatremia is common in cART naïve HIV-infected patients (14.8%)
- Baseline hyponatremia is associated with an increased risk of mortality in HIV patients in univariate analysis
- Hyponatremia is not an independent risk factor for mortality
- Hyponatremia is a marker of severity of HIV-related disease
- Serum sodium concentration correlates positively with CD4 cell count
- HIV-patients with a low serum sodium at baseline might benefit from a close follow-up to improve outcomes



Acid-base/Na, K, Cl, uric acid.

DOI: 10.3252/pso.eu.53era.2016





Poster. Session

line